Clinical Trials Logo

Purpura clinical trials

View clinical trials related to Purpura.

Filter by:

NCT ID: NCT01931644 Completed - Breast Cancer Clinical Trials

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Start date: July 2013
Phase:
Study type: Observational

We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.

NCT ID: NCT01910831 Completed - Purpura Clinical Trials

Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands

CCCR-28-2013
Start date: July 2013
Phase: Phase 4
Study type: Interventional

To determine the efficacy (measured at 12 weeks) of DerMend Moisturizing Bruise Formula in improving the appearance of bruising and reducing the appearance of photoaging of the forearms and hands in mature skin. Assessments will be made through ongoing objective measurements and clinical ratings. To confirm the safety (local tolerance) of DerMend Moisturizing Bruise Formula.

NCT ID: NCT01808521 Completed - Clinical trials for Purpura, Thrombotic Thrombocytopenic

A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura

NACinTTP
Start date: May 2013
Phase: Early Phase 1
Study type: Interventional

In this study, the investigators want to determine if N-acetylcysteine(NAC), given intravenously, will decrease complications in patients with Thrombotic Thrombocytopenia Purpura (TTP) who are receiving treatment with therapeutic plasma exchange (TPE). The investigators want to determine, through anti-oxidant activity, if NAC will have additional efficacy in TTP by improving cleavage of the patients' VWF by ADAMTS13, and preventing propagation of platelet/VWF strings. This will be manifest by a more rapid improvement in the patient's platelet count, decrease in number of days requiring TPE, and decrease in microvascular thrombotic complications. The investigators will additionally: 1) Assess safety of NAC by evaluating subjects for adverse events and significant adverse events 2) Determine effects on TTP by measuring clinical and research laboratory values 3) Determine drug effects by measuring clinical and research laboratory values.

NCT ID: NCT01762761 Completed - Clinical trials for Purpura, Thrombocytopenic, Idiopathic and Hepatitis C

Eltrombopag Phase III Study In Chinese Chronic ITP Patients

Start date: February 18, 2013
Phase: Phase 3
Study type: Interventional

This randomized, double-blind and open-label phase III study aimed to determine the efficacy, tolerance and safety of eltrombopag in Chinese chronic primary immune thrombocytopenia (ITP) adult subjects. This study was be conducted in Chinese adult chronic ITP subjects who had not responded to or had relapsed after previous treatment of ITP, including first line therapy and /or splenectomy. The primary objective of this study was to determine the efficacy of oral eltrombopag as a thrombopoietic agent treating previously treated chronic Chinese ITP patients compared to placebo. The secondary objective was to assess the safety and tolerability of eltrombopag when administered for 6 weeks to previously treated adult chronic ITP patients compared with placebo. In addition, the long-term efficacy and safety of eltrombopag treatment was also evaluated in the 24-week extension open-label phase after the double-blind phase as one of other study objectives. If the subject benefited from the eltrombopag treatment based on the investigator's discretion, the subject could continue on eltrombopag treatment until the commercial launch of eltrombopag in China. Furthermore, to understand the pharmacokinetics (PK) profile of eltrombopag and to explore the relationship between the PK and pharmacodynamics (PD) (platelet response), a PK/PD analysis was embedded in this phase III study and conducted in the same patient population who participated this phase III study.

NCT ID: NCT01734044 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP

Start date: July 2012
Phase: Phase 3
Study type: Interventional

The project was undertaking by Qilu Hospital of Shandong University and other 13 well-known hospitals in China. In order to report the efficacy and safety of Recombinant Human thrombopoietin combining with Dexamethasone for the treatment of adults with primary immune thrombocytopenia (ITP), compared to High-dose Dexamethasone therapy.

NCT ID: NCT01730352 Completed - Clinical trials for Helicobacter Pylori Infection

Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients

Start date: October 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether eradication of Helicobacter pylori infection is effective in the improvement of platelet counts in children and adolescents with chronic ITP.

NCT ID: NCT01719692 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia

ITP
Start date: October 2012
Phase: N/A
Study type: Interventional

A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this study is to compare the efficacy and tolerability of two different regimens of low doses rituximab for the treatment of adult patients with ITP.

NCT ID: NCT01713855 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

Start date: October 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to determine how children with a history of severe, chronic Idiopathic Thrombocytopenic Purpura (ITP) who were treated with rituximab might respond to vaccines. Eligible patients are previously or currently enrolled in a study entitled "Open Label, Phase I/II Trial of Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura in Children and Adolescents" and have decided to obtain an inactivated influenza vaccination. These patients will be invited to provide one blood sample prior to vaccination and a second sample following vaccination to quantify immune response to vaccination.

NCT ID: NCT01713738 Completed - Clinical trials for Immune Thrombocytopenic Purpura (ITP)

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Start date: May 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of rituximab in children ages 18 months to 18 years, who have severe, chronic ITP. Eligible patients with either primary or secondary ITP are treated with rituximab once a week for 4 doses, and then followed for up to one year. Response is defined as having a platelet count greater than or equal to 50,000/mL on four consecutive weekly measures beginning anytime in weeks 9 - 12.

NCT ID: NCT01621204 Completed - Clinical trials for Immune Thrombocytopenic Purpura

A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

Start date: October 2012
Phase: Phase 3
Study type: Interventional

This is a study to investigate if eltrombopag can be used instead of Intravenous Immune Globulin (IVIG) in patients with ITP, to adequately raise their platelet count when they undergo minor or major surgery. Eltrombopag is a daily, oral pill approved for treatment of ITP. IVIG is a blood product frequently used to treat ITP. Patients with ITP who need surgery have to get treatment to increase their platelet count. IVIG is commonly used for this purpose but eltrombopag may be more effective and convenient for patients.